Drawing for Serial No. 88146199

USPTO serial 88146199

Serial No. 88146199

Reviewed by CopyMark Law Group

Reg. 6072267Status 702Renewal
Filing date
Status date
Registration date
Jun 9, 2020
Examiner
SINGH, TEJBIR
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with Serial No. 88146199?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,795*

Plus Government fees of $2,125

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Angela P. Doughty

Angela P. Doughty WARD AND SMITH, P.A.751 Corporate Center Drive, Suite 300Post Office Box 33009RALEIGH, NC 27607

Goods and services

ClassDescriptionStatusFirst use
009Downloadable electronic newsletters delivered by e-mail in the field of biopharmaceuticals and biotechnologyACTIVE—
016Printed matter, namely, books, reports, leaflets, pamphlets, flyers, articles, information sheets, manuals, newsletters, periodicals and journals all in the field of healthcare, medical technology, medical devices, life sciences, pharmaceuticals, biotechnology or biopharmaceuticals; printed matter, namely, books, reports, leaflets, pamphlets, flyers, articles, information sheets, manuals, newsletters, periodicals and journals all in the biopharmaceutical field; printed matter, namely, books, reports, leaflets, pamphlets, flyers, articles, information sheets, manuals, newsletters, periodicals and journals all in the biotechnology field; research reports featuring biopharmaceutical and biotechnology dataACTIVE—
035Business development services; business advisory services relating to product development; business project management for others in the fields of biopharmaceuticals and biotechnology; business management consultancy; corporate management consultancy; commercial management consultancy; business consultancy; business information; market research; business services, namely, formulation of best practices in the biopharmaceutical and biotechnology fields; expert evaluations and reports relating to business matters; conducting business and market research surveys; collection of market research information; analysis of market research data and statistics; computerized market research services; preparation of business reports; provision of marketing reports; market reports and studies; promoting collaboration within the science and research communities; promoting collaboration within the science and research communities to achieve advances in the field of biopharmaceuticals and biotechnology; promoting the exchange of information within the science and research communities; promoting the exchange of information within the science and research communities to achieve advances in the field of biopharmaceuticals and biotechnology; business research; business research consultation; arranging and conducting business conferences; providing an in-person business forum in the fields of biopharmaceuticals and biotechnology; business consultancy to the biotechnology and biopharmaceuticals industry; business introduction services; business project management services in the field of healthcare, medical technology, medical devices, life sciences, pharmaceuticals, biotechnology or biopharmaceuticalsACTIVE—
041Arranging and conducting seminars, workshops, educational conferences, and educational teleconferences, all in the field of healthcare, medical technology, medical devices, life sciences, pharmaceuticals; arranging and conducting seminars, workshops, educational conferences, and educational teleconferences, all in the field of biotechnology and biopharmaceuticals; business training services; providing online training in the form of courses, seminars and workshops in the fields of biopharmaceuticals and biotechnology; providing an in-person educational forum in the fields of biopharmaceuticals and biotechnology; publishing services, namely, publishing of electronic publications in the field of healthcare, medical technology, medical devices, life sciences, pharmaceuticals, biotechnology or biopharmaceuticals; publishing of electronic publications in relation to regulatory matters, scientific matters, business information, product development, product supply chain, biopharmaceuticals and biotechnology industry and technology; education services, namely, arranging and conducting seminars, workshops, educational conferences, educational teleconferences, and online educational courses, in the field of healthcare, medical technology, medical devices, life sciences, pharmaceuticals, biotechnology or biopharmaceuticals; On-line electronic newsletters delivered by e-mail in the field of biopharmaceuticals and biotechnologyACTIVE—
042Compiling data for research purpose in the field of medical science and medical consultancy; product development consultation; pharmaceutical research and development; consultancy on pharmaceutical product development, biopharmaceutical product development, biotechnology product development, medical device product development; technical research in the field of pharmaceutical studies; technical research in the field of biopharmaceuticals, biotechnology, medical devices and life science studies; technical consulting in the field of pharmaceutical studies; consultancy in the field of pharmaceutical research; testing, inspection, research, or development of pharmaceutical preparations; research on the subject of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals; providing medical and scientific research information in the field of biopharmaceuticals, biotechnology, medical devices and life sciences; Developing quality control standards for pharmaceutical, biopharmaceutical and medical device manufacturing; Consultancy services in relation to developing quality control standards for pharmaceutical, biopharmaceutical and medical device manufacturing; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the field of for pharmaceuticals, biopharmaceuticals, biotechnology, and medical devices; Consultancy services in relation to quality evaluation and analysis, quality assurance, and quality control, in the field of for pharmaceuticals, biopharmaceuticals, biotechnology, and medical devices; Advisory in the field of quality control of manufactured goodsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 4, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 4, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 3, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 8, 2026E815TEAS SECTION 8 & 15 RECEIVED—
Jun 9, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jun 9, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 24, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 24, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 4, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 20, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 20, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Feb 19, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 19, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 19, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 18, 2019GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Sep 18, 2019GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 18, 2019CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 14, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 14, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 9, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 9, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 9, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 25, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 25, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 25, 2019ALIEASSIGNED TO LIE—
Jul 19, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 21, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 21, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 21, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 17, 2019DOCKASSIGNED TO EXAMINER—
Oct 18, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Oct 17, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 12, 2018TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Oct 12, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Oct 11, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance